Streetbeat News

Analyst Ratings

CRBP

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) presented results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The studies demonstrated robust pre-clinical anti-tumor activity of CRB-601, alone and in combination with anti-PD-1 therapy. The company plans to submit an Investigational New Drug application for CRB-601 by the end of 2023 and expects to initiate its Phase 1 study by the end of June 2024.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:23 pm

CLX

CORT

EAT

GNRC

MSTR

PTC

PYPL

ROKU

TENB

Top Wall Street analysts have updated their outlooks on several stocks. Tenable Holdings' price target was cut from $55 to $45 by Needham. Citigroup increased the price target for Clorox from $135 to $150. Pivotal Research raised Roku's price target from $58 to $75. Stifel raised the price target for Generac Holdings from $130 to $135. HC Wainwright & Co. increased the price target for Corcept Therapeutics from $32 to $34. Canaccord Genuity increased MicroStrategy's price target from $513 to $554 and cut PayPal's price target from $110 to $100. Piper Sandler increased PTC's price target from $150 to $155. RBC Capital cut Estée Lauder's price target from $195 to $115. Wedbush increased Brinker International's price target from $33 to $37.

Portfolio Pulse from Lisa Levin

November 02, 2023 | 12:16 pm

SEDG

Truist Securities analyst Jordan Levy has downgraded SolarEdge Technologies from Buy to Hold and lowered the price target from $120 to $70.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:13 pm

CLRB

Cellectar Biosciences is set to release top-line data from its Waldenstrom's Macroglobulinemia (WM) pivotal trial during the JP Morgan Healthcare Conference.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:11 pm

NSIT

Insight Enterprises reported Q3 earnings of $2.37 per share, beating the analyst consensus estimate of $2.33 by 1.72%. However, the company's quarterly sales of $2.27 billion missed the analyst consensus estimate of $2.36 billion by 3.97%. This represents a 19.1% increase in earnings but a 10.56% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:03 pm

GERN

Geron (NASDAQ:GERN) reported Q3 losses of $(0.08) per share, beating the analyst consensus estimate of $(0.10) by 20%. The company also reported quarterly sales of $164.00K, surpassing the analyst consensus estimate of $59.00K by 177.97%. However, this represents a 44.78% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 12:01 pm

TTD

New Street Research analyst Dan Salmon has upgraded Trade Desk (NASDAQ:TTD) from Sell to Neutral.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:58 am

TOL

Seaport Global analyst Mark Weintraub has upgraded Toll Brothers (NYSE:TOL) from Neutral to Buy and set a price target of $93.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:56 am

MSGS

Madison Square Garden (NYSE:MSGS) reported Q1 losses of $(0.79) per share, beating the analyst consensus estimate of $(1.51) by 47.68%. The company also reported quarterly sales of $43.00 million, surpassing the analyst consensus estimate of $24.85 million by 73.04%. However, this represents a 8.22% decrease in losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:54 am

TMHC

Seaport Global analyst Kenneth Zener has upgraded Taylor Morrison Home (NYSE:TMHC) from Neutral to Buy and set a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:53 am